Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Reported Basic Consolidated EPS Of $13.0018 For Period Ended 2015-12-31

0

The annual basic consolidated EPS for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for the period ended 2015-12-31 was $13.0018. On quarterly basis, the basic consolidated EPS reading for the quarter ended 2015-12-31 was $13.0018.

EPS from continuing operations

Coming to basic EPS from continuing operations, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported $13 for the annual period ended 2015-12-31. Quarterly basic EPS from continuing operations for the three-month period ended 2015-12-31 stood at $13.

EPS contribution from parent

For the annual period ended 2015-12-31, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) received basic EPS of $13.0018 from its parent company. On quarterly basis, basic EPS contribution from the parent company for the period ended 2015-12-31 was $13.0018.

Basic net EPS

For the annual period ended 2015-12-31, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported basic net EPS of $13. On quarterly basis, the company’s basic net EPS for the three-month period ended 2015-12-31 stood at $13.

Consolidated diluted EPS

The annual consolidated diluted EPS reading for the period ended 2015-12-31 stood at $12.121. For the quarter ended 2015-12-31, consolidated diluted EPS was $12.121.

Basic diluted EPS

On annual basis, diluted EPS reading from continuing operation was $12.12 for the period ended 2015-12-31. Diluted EPS from continuing operations for the quarter ended 2015-12-31 was $12.12.

Net diluted EPS

Net diluted EPS reading for the annual period ended 2015-12-31 was $12.12. For the quarterly period ended 2015-12-31, net diluted EPS was $12.12.

Diluted EPS from parent

From the parent company, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) received diluted EPS of $12.121 for the annual period ended 2015-12-31. On quarterly basis, diluted EPS contribution from the parent for the quarter ended 2015-12-31 was $12.121.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted net basic EPS reading of $13 for the annual period ended 2015-12-31. For the quarter, basic net EPS of $13 was for the quarter ended 2015-12-31.

Net diluted EPS for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for the annual period ended 2015-12-31 was $12.12. The company also reported net diluted EPS reading of $12.12 for the quarter ended 2015-12-31.

The annual average basic shares outstanding for the period ended 2015-12-31 is 19.79 while for the quarter ended 2015-12-31 is 19.79.

The diluted shares outstanding for the fiscal year ended is 2015-12-31 is 21.228 while for the quarter ended 2015-12-31 is 21.228.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 9 times, 1 visits today)